苏黄止咳胶囊联合布地奈德雾化吸入治疗咳嗽变异性哮喘的临床观察

目的 观察苏黄止咳胶囊联合布地奈德雾化吸入治疗咳嗽变异性哮喘(CVA)的临床治疗效果.方法 2016年1-12月保定市第一中心医院收治的60例CVA患者随机分为对照组、观察组各30例,2组患者均给予常规西药药物及吸入用布地奈德雾化吸入治疗,观察组在对照组基础上加服苏黄止咳胶囊,观察4周后2组患者肺功能肺活量(FVC)、峰流速仪记录最大呼气峰流速(PEF)、1秒率(FEV1/FVC)]、外周血嗜酸性粒细胞计数(EOS)及血清肿瘤坏死因子-α(TNF-α)、白细胞介素-5(IL-5)水平变化.结果 治疗前2组患者FVC、PEF、FEV1/FVC、EOS、TNF-α、IL-5比较,差异均无统计学意义(P>0.05).治疗4周后与对照组比较,观察组患者FVC、PEF、FEV1/FVC明显升高(P<0.05),EOS、TNF-α、IL-5水平均降低(P<0.05).观察组总有效率93.33%明显高于对照组73.33%(P<0.05).结论 苏黄止咳胶囊联合布地奈德雾化吸入治疗咳嗽变异性哮喘明显改善临床症状及肺功能,疗效显著.

Clinical observation of the effect of suhuangzhike capsule combined with Budesonide aerosol inhalation in the treatment of patients with cough variant asthma

Objective To observe the effect of suhuangzhike capsule combined with Budesonide aerosol inhalation in the treatment of patients with cough variant asthma. Methods 60 patients with cough variant asthma were randomly divided into the con-trol group and study group which were both 30 cases and were given conventional western medicine and Budesonide aerosol inhalation. The study group was given suhuangzhike capsule additionally. After 4 weeks, the two groups were observed the chang of lung function, peripheral blood eosinophil count, TNF-α and IL-5. Results There was no difference in FVC, PEF, FEV1/FVC, EOS, TNF-αand IL-5 in the two groups before treatment ( P>0. 05) . In the study group, FVC, PEF and FEV1/FVC were increased ( P<0. 050) , the levels of serum EOS, TNF-α and IL-5 were decreased compared with control group after treatment for 4 weeks (P<0. 05). The clinical efficacy in the study group was better than that in the control group ( 93. 33% vs 73. 33%, P<0. 05) . Conclusion Suhuang-zhike capsule combined with Budesonide aerosol inhalation could significantly improve the clinical symptoms and lung function.